Best Elahere (Mirvetuximab Soravtansine) Medicine in India

Elahere (Mirvetuximab Soravtansine) is a targeted anticancer treatment used for adults with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after previous systemic treatments. It is an antibody-drug conjugate that specifically targets FRα on cancer cells and delivers a cytotoxic component directly to these cells, helping to slow cancer growth and progression.

Elahere (Mirvetuximab Soravtansine) is administered by a healthcare professional through an intravenous infusion. The dose and treatment schedule are determined by your doctor based on your body weight, medical condition, and response to treatment. Regular eye examinations and laboratory tests may be required during treatment because this medicine can cause eye-related problems and other side effects.

Common side effects of Elahere (Mirvetuximab Soravtansine) may include blurred vision, dry eyes, eye irritation, fatigue, nausea, diarrhea, abdominal pain, decreased appetite, and changes in liver function. Serious eye problems can occur, so report any new or worsening vision changes promptly. Before starting treatment, inform your doctor about your medical history and all medicines, vitamins, herbal products, or dietary supplements you are taking.

Treatment of Folate Receptor Alpha (FRα)-Positive Ovarian Cancer

Elahere (Mirvetuximab Soravtansine) is used to treat adults with FRα-positive, platinum-resistant ovarian cancer, as well as certain fallopian tube and primary peritoneal cancers, after previous systemic treatments. It targets folate receptor alpha (FRα) found on cancer cells and delivers its anticancer component directly to these cells. This helps destroy abnormal cancer cells, slow tumor growth, and control disease progression.

Some side effects of Elahere (Mirvetuximab Soravtansine) may improve as your body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Elahere (Mirvetuximab Soravtansine)

Elahere (Mirvetuximab Soravtansine) is administered by a healthcare professional through an intravenous infusion. The dose and treatment schedule are determined by your doctor based on your body weight, medical condition, and response to treatment. Eye examinations and regular medical tests are required before and during treatment. Use the prescribed eye drops as directed by your doctor and report any vision changes promptly.

Elahere (Mirvetuximab Soravtansine) is an antibody-drug conjugate (ADC) that targets folate receptor alpha (FRα) found on certain cancer cells. After binding to FRα, it is taken into the cancer cell and releases its cytotoxic component, which interferes with cell division and leads to cancer cell death. This targeted action helps slow the growth and spread of FRα-positive ovarian cancer.

• Maintain the unopened vial under refrigeration at 2°C to 8°C.
• Do not allow the vial to freeze, and keep it protected from excessive heat.
• Retain the vial in its original carton to shield it from light exposure.
• Once diluted, store and use the infusion solution within the time and temperature limits specified in the prescribing information.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Elahere (Mirvetuximab Soravtansine).

Pregnancy CONSULT YOUR DOCTOR

Elahere (Mirvetuximab Soravtansine) may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant.

Breastfeeding CONSULT YOUR DOCTOR

Breastfeeding is not recommended during treatment with Elahere (Mirvetuximab Soravtansine). Consult your doctor for guidance.

Driving CONSULT YOUR DOCTOR

Elahere (Mirvetuximab Soravtansine) may cause blurred vision or other eye problems that can affect driving. Avoid driving if your vision is affected.

Kidney CAUTION

Inform your doctor if you have kidney problems before receiving Elahere (Mirvetuximab Soravtansine). Your doctor will determine the appropriate treatment and monitoring.

Liver CAUTION

Tell your doctor if you have liver problems. Liver function may be monitored during treatment with Elahere (Mirvetuximab Soravtansine).

• Attend all scheduled eye examinations before and during treatment with Elahere (Mirvetuximab Soravtansine) to monitor your eye health.
• Use prescribed lubricating and steroid eye drops exactly as directed by your healthcare professional.
• Report blurred vision, dry eyes, eye pain, increased sensitivity to light, or other new eye symptoms immediately and avoid contact lenses unless your doctor confirms they are safe to use during treatment.
• Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible interactions.
• Contact your doctor promptly if you develop severe fatigue, breathing difficulties, persistent diarrhea, or other unusual symptoms.
• Read More About - Elahere (Mirvetuximab Soravtansine) from Pharma Five.

Pharma Five, may assist patients with the import of Elahere (Mirvetuximab Soravtansine) in small quantities for personal use. To proceed with the import, the applicant needs to submit an application in Form 12A along with a prescription issued by a Registered Medical Practitioner (RMP).

Pharma Five offers professional support to patients seeking access to Elahere (Mirvetuximab Soravtansine), along with other specialized pharmaceutical products, through experienced import facilitation services. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.